The Role of Antibody Testing for SARS-CoV-2: Is There One?
Top Cited Papers
Open Access
- 23 July 2020
- journal article
- editorial
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 58 (8)
- https://doi.org/10.1128/jcm.00797-20
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brought with it rapid development of both molecular and serologic assays for identification of COVID-19 infections. While Food and Drug Administration (FDA) emergency use authorization (EUA) is required for clinical application of SARS-CoV-2 molecular tests, submission for EUA is currently a voluntary process for manufacturers of serologic assays. The absence of FDA oversight of serologic tests is concerning, given that the commercially available serologic assays are highly variable, differing in their format, the antibody class detected, the targeted antigen and the acceptable specimen types. An added complication is the lack of a clear understanding for how such assays should be utilized and what the reported results ultimately indicate, or perhaps more importantly, what they do not indicate. Here, we provide a brief summary of the performance of a number of serologic assays reported in the literature, comment on what we do and do not know regarding our immune response to SARS-CoV-2, and provide a number of scenarios for which serologic testing will play a role in during our global response to this pandemic.Keywords
Funding Information
- Mayo Clinic
This publication has 24 references indexed in Scilit:
- The convalescent sera option for containing COVID-19JCI Insight, 2020
- The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2Nature Microbiology, 2020
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)Clinical Infectious Diseases, 2020
- Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2Published by Cold Spring Harbor Laboratory ,2020
- Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020Eurosurveillance, 2020
- IgA and FcαRI: Pathological Roles and Therapeutic OpportunitiesFrontiers in Immunology, 2019
- Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up StudyThe Journal of Immunology, 2011
- "Herd Immunity": A Rough GuideClinical Infectious Diseases, 2011
- Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in SerumClinical and Vaccine Immunology, 2010
- Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirusClinical Microbiology & Infection, 2004